Pharmaceutical

BR-6002 by Boryung Pharmaceutical for Duodenal Ulcer: Likelihood of Approval

BR-6002 is under clinical development by Boryung Pharmaceutical and currently in Phase I for Duodenal Ulcer.

Aug 28, 2023 - 20:00
BR-6002 is under clinical development by Boryung Pharmaceutical and currently in Phase I for Duodenal Ulcer.
Read the original article

Tags:

Previous Article

Lutetium (lu177) lilotomab satetraxetan by Thor Medical for B-Cell Chronic Lymph...

Next Article

BR-6002 by Boryung Pharmaceutical for Gastric Ulcers: Likelihood of Approval

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

STAT+: Annexon’s trial of an eye disease drug missed by a mile. The company saw a bull’s eye

STAT+: Annexon’s trial of an eye disease drug missed by...

May 25, 2023

An effort to diversify genetic research finds new variant for Parkinson’s disease in African populations

An effort to diversify genetic research finds new varia...

Aug 25, 2023

STAT+: Wegovy may have another helpful trick: fighting inflammation via the brain, study finds

STAT+: Wegovy may have another helpful trick: fighting ...

Dec 19, 2023